Roche amps up its bis­pe­cif­ic at­tack on Eylea with more PhI­II da­ta — but just how threat­en­ing is it?

Roche has an­oth­er stack of da­ta to back up its longer-act­ing chal­lenger to Eylea — al­though it’s still far from cer­tain just how much they can threat­en Re­gen­eron’s dom­i­nance.

The lat­est Phase III re­sults come from two tri­als that en­rolled 1,329 pa­tients with neo­vas­cu­lar age-re­lat­ed mac­u­lar de­gen­er­a­tion. With 45% of peo­ple in both stud­ies get­ting faricimab 16 weeks apart dur­ing the first year, the bis­pe­cif­ic still in­duced the same lev­el of gains in vi­su­al acu­ity as Eylea every 8 weeks did, Roche’s Genen­tech re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER